A Flood in Genomics

Nine months have passed since draft sequences of the human genome were first published.1,2 One human gestation period later, the genome, as deciphered by the International Human Genome Sequencing Consortium, still screams toward its projected Spring 2003 finish date. "The trajectory we're on for meeting that goal is precisely on target," assures Francis Collins, director, National Human Genome Research Institute (NHGRI) and spokesperson for the largest public biological science project in histor

Written byBrendan Maher
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

According to Collins, 55 percent of the genome is in completed form and 42 percent is in draft form. Chromo- somes 20 and Y are finished and being written up, with 6, 7, and 14 close behind. Each is sure to offer new insights to human health and life itself. But as the torrents of genomic data continue to pour in from the human genome and a myriad of other organisms, scientists are forced to valuate the data before them. As a tool for basic researchers, the human genome has been well used. Both publications on the draft genome have been cited in more than 350 papers, according to the Web of Science, ISI, Philadelphia. Yet, financial onlookers say that pharmaceutical companies may be choked by the wealth of data. And still, the flood continues as projects in proteomics and transcriptomics open up new holes in the dam.

"In the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies